acne: An inflammatory process of the sebaceous glands which is characterized by comedones, nodules, papules and/or pustules on the skin.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
89 |
4. Check minimum number of eventsNone |
89 |
5. Include endpointsNone |
89 |
6. Filter based on genotype QC (FinnGen only) |
89 |
Control definitions (FinnGen only)
- Control exclude
- L12_DISORDSKINAPPENDIX
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L70
- Name in latin
- Acne varioliformis
Similar endpoints
↥List of similar endpoints to
Acne varioliformis
based on the number of shared cases.
Similar with more cases:
- Acne
- Disorders of skin appendages
- Diseases of the skin and subcutaneous tissue
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 575 | 296 | 276 |
| Only index persons | 520 | 275 | 245 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 54.38 | 52.45 | 56.29 |
| Only index persons | 51.46 | 50.11 | 52.97 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 89 | 50 | 39 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 50.91 | 47.48 | 55.29 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 85
- Matched controls
- 849
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L70.2
ICD-10 Finland
Acne varioliformis
7607.2
108.5
81
*
L73.2
ICD-10 Finland
Hidradenitis suppurativa
+∞
10.6
10
*
A10AE04
ATC
insulin glargine; parenteral
7.1
8.2
20
35
E11.7
ICD-10 Finland
Type 2 diabetes mellitus, with multiple complications
12.6
8.1
14
13
177
Kela drug reimbursment
Insulin glargine 300 U / ml
49.7
7.9
9
*
N05BA04
ATC
oxazepam; oral
4.0
7.5
35
126
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
13.7
7.3
12
10
XPX99
NOMESCO Finland
Other diagnostic examination of periferal vessel
8.9
7.3
15
20
TPH07
NOMESCO Finland
Cathetrisation of artery
7.3
7.2
17
28
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
6.3
7.2
19
37
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
5.1
6.9
22
54
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
11.4
6.8
12
12
S97
ICPC
Chronic ulcer skin
8.1
6.5
14
20
PD4CG
NOMESCO Finland
Extensive MRI examination of abdominal aortta and vasculature of lower extremities with high intensity magnet
75.3
6.5
7
*
F32.9
ICD-10 Finland
Depressive episode, unspecified
4.9
6.4
21
53
PE1AT
NOMESCO Finland
Femoral artery PTA
+∞
6.3
6
*
PF1AT
NOMESCO Finland
Intravascular dilatation of arteries of knee, lower leg and ankle (PTA)
+∞
6.3
6
*
SPAT1148
SPAT
Treatment of chronic ulcer or burn
4.8
6.3
21
54
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
13.9
6.3
10
8
N06AX16
ATC
venlafaxine; oral
4.6
6.1
21
56
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
18
47
4.55
6.64
2.0
1.3
—
—
—
0
0
29
110
3.43
6.36
1.7
1.9
1338.3
1292.4
nmol/l
0.08
19
85
50
276
2.85
5.55
2.1
1.9
89.5
98.4
pmol/l
0.54
24
142
21
70
3.62
5.55
2.0
3.1
22.5
28.3
u/l
0.84
15
59
21
77
3.26
4.75
8.2
3.7
—
—
—
0
0
50
296
2.57
4.57
14.3
6.0
1.2
1.2
mmol/l
0.07
43
274
50
298
2.55
4.48
7.3
3.8
33.8
35.7
g/l
1.00
42
283
63
426
2.64
4.22
18.5
8.7
5.0
4.3
e9/l
0.93
55
380
76
570
3.28
4.08
10.9
6.8
91.7
75.9
u/l
1.67
71
535
9
16
6.12
3.76
3.4
1.7
—
—
—
0
0
51
325
2.33
3.72
14.0
6.4
1.2
1.2
mmol/l
0.60
40
269
40
233
2.30
3.56
4.8
2.7
2.4
2.4
mmol/l
0.08
35
207
9
21
4.64
3.09
2.2
2.2
—
—
—
0
0
36
212
2.17
3.03
3.7
2.5
2.6
0.4
e6/l
0.60
31
163
20
91
2.54
3.01
1.9
2.8
4.4
9.0
umol/l
0.67
13
78
58
417
2.12
2.84
11.3
4.7
8.3
6.6
mmol/l
2.88
53
386
7
14
5.33
2.78
1.9
1.6
—
—
—
0
0
7
14
5.33
2.78
1.9
1.6
—
—
—
0
0
69
536
2.28
2.70
5.0
3.6
18.0
11.2
mm/h
1.52
60
497
21
104
2.33
2.63
3.7
2.8
3.7
2.3
e6/l
0.24
15
60
42
275
2.00
2.59
4.1
2.8
—
—
—
0
0
5
7
7.48
2.58
4.6
1.0
—
—
—
0
0
31
182
2.08
2.57
1.5
1.2
2.7
1.2
u/ml
—
5
51
6
12
5.27
2.44
1.2
1.3
—
—
—
0
0
17
79
2.42
2.44
2.2
1.7
—
—
—
0
0
21
108
2.24
2.41
2.2
1.8
—
—
—
0
0
24
131
2.14
2.38
3.9
3.4
490.1
224.4
ng/l
0.32
16
91
21
110
2.19
2.30
3.2
2.3
1.5
1.1
e6/l
0.21
15
64
27
157
2.03
2.27
4.3
2.1
—
—
—
0
0
31
190
1.97
2.25
1.5
1.6
1.5
1.3
mmol/l
0.80
26
161
80
689
2.59
2.20
28.3
12.6
86.0
85.2
ml/min/173m2
0.09
70
579
27
160
1.99
2.14
1.9
1.7
0.9
1.0
mg/l
0.04
16
133
68
547
2.03
2.12
5.0
3.6
14.6
14.7
pmol/l
0.17
63
495
7
20
3.71
2.10
2.0
2.1
—
—
—
0
0
5
10
5.22
2.10
2.0
1.1
—
—
—
0
0
51
377
1.83
2.03
6.1
6.0
10.2
10.5
umol/l
0.14
46
360
11
45
2.65
2.02
1.8
1.2
—
—
—
0
0
5
11
4.74
1.97
1.4
1.6
—
—
—
0
0
15
76
2.17
1.77
2.3
1.7
—
—
—
0
0
44
321
1.73
1.75
4.8
2.5
150.7
92.2
ug/l
0.84
38
301
7
25
2.95
1.69
1.7
1.1
—
—
—
0
0
11
51
2.32
1.58
1.0
1.2
—
85.6
iu/ml
—
0
21
81
733
2.17
1.43
35.2
13.1
25.7
23.3
mg/l
0.32
72
568
6
23
2.72
1.39
2.8
1.3
—
—
—
0
0
21
132
1.77
1.36
1.5
1.2
52.7
36.0
iu/ml
—
5
37
44
339
1.59
1.32
6.5
3.7
—
—
—
0
0
8
41
2.04
1.12
1.5
1.4
—
—
—
0
0
7
32
2.29
1.11
4.7
2.0
1.0
1.8
%
—
7
32
9
46
2.06
1.07
2.3
1.8
—
—
—
0
0
9
48
1.97
1.04
1.6
2.3
303.9
199.8
ng/l
—
9
41
73
654
1.65
0.99
7.9
5.4
45.2
39.9
mmol/mol
1.82
68
614
6
31
2.00
0.86
2.5
1.5
—
—
—
0
0
83
780
1.95
0.78
30.2
14.7
82.3
76.1
umol/l
0.44
83
780
19
136
1.50
0.75
1.6
1.8
454.0
471.2
pmol/l
0.09
14
115
17
124
1.46
0.61
1.5
1.3
1.1
5.1
u/ml
—
9
43
9
61
1.53
0.56
3.1
1.9
—
—
—
0
0
31
258
1.31
0.52
5.2
3.7
16.8
38.5
ng/l
1.41
21
169
23
183
1.35
0.52
3.1
3.1
6700.9
1282.8
ng/l
0.87
18
152
77
726
1.45
0.51
5.5
4.6
2.5
2.7
mmol/l
1.10
67
676
8
60
1.37
0.41
9.3
2.6
5.8
5.8
kpa
—
8
60
0
19
0.00
0.39
0.0
1.1
—
—
—
0
0
6
46
1.33
0.34
1.0
1.1
—
—
—
0
0
25
215
1.23
0.31
5.4
3.4
0.0
0.0
estimate
—
9
79
10
80
1.28
0.21
9.4
6.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.8
—
—
—
0
0
14
163
0.83
0.19
2.6
1.5
—
—
—
0
0
74
717
1.19
0.18
5.0
4.1
4.3
4.6
mmol/l
1.88
66
673
50
527
0.88
0.18
4.0
3.4
—
—
—
0
0
8
67
1.21
0.17
2.6
1.8
379.6
364.6
nmol/l
—
8
62
6
76
0.77
0.16
6.2
4.8
24.8
33.1
%
—
6
52
68
701
0.87
0.15
5.3
4.2
7.1
5.9
mmol/l
1.72
61
645
13
113
1.18
0.14
3.4
2.2
—
—
—
0
0
73
713
1.13
0.11
4.9
4.1
1.2
1.4
mmol/l
4.05
66
663
14
127
1.12
0.08
1.3
1.4
—
—
—
0
0
39
374
1.08
0.08
4.5
3.0
0.0
0.0
estimate
0.00
11
83
39
374
1.08
0.08
5.5
4.1
0.0
0.0
estimate
—
10
81
28
294
0.93
0.07
4.7
3.2
—
—
—
0
0
13
120
1.10
0.05
4.0
2.3
—
—
—
0
0
39
379
1.05
0.04
4.5
3.1
0.0
0.0
estimate
—
10
76
69
691
0.99
0.00
4.4
3.7
1.5
1.3
mmol/l
1.04
61
642
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
5.4
—
208.7
—
0
7
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
2.3
—
13.4
—
0
7
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
0.1
—
0
5
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
5.8
—
0
6
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
53
530
1.00
0.00
4.9
2.9
83.2
41.4
u/l
0.92
44
509
0
5
0.00
0.00
0.0
3.0
—
52.4
—
0
5
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
1524.2
—
0
5
0
5
0.00
0.00
0.0
3.6
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.9
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_ACNE_VARIOLIFORMIS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_ACNE_VARIOLIFORMIS | 3.159 [1.69, 5.9] | < 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.158 |
During the follow-up period (1.1.1998 — 31.12.2019), 69 out of 248 females with L12_ACNE_VARIOLIFORMIS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_ACNE_VARIOLIFORMIS | 2.79 [1.74, 4.47] | < 0.001 |
| Birth year | 0.985 [0.97, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 74 out of 222 males with L12_ACNE_VARIOLIFORMIS died.
Mortality risk
Mortality risk for people of age
years, who have L12_ACNE_VARIOLIFORMIS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.295% | 0.545% |
| 5 | 1.815% | 3.121% |
| 10 | 4.642% | 7.312% |
| 15 | 8.799% | 13.825% |
| 20 | 14.855% | 22.752% |
Relationships between endpoints
↥Index endpoint: L12_ACNE_VARIOLIFORMIS – Acne varioliformis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data